Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nevus, Pigmented | 16 | 2024 | 222 | 6.710 |
Why?
|
Skin Neoplasms | 48 | 2024 | 5860 | 6.310 |
Why?
|
Melanoma | 33 | 2024 | 5702 | 4.540 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 7 | 2024 | 67 | 4.340 |
Why?
|
Melanosis | 4 | 2023 | 93 | 2.220 |
Why?
|
Dermatology | 12 | 2023 | 905 | 2.060 |
Why?
|
Dermoscopy | 3 | 2024 | 73 | 1.660 |
Why?
|
Pigmentation Disorders | 2 | 2022 | 105 | 1.520 |
Why?
|
Basal Cell Nevus Syndrome | 2 | 2022 | 38 | 1.470 |
Why?
|
Skin | 12 | 2023 | 4499 | 1.350 |
Why?
|
Hair Diseases | 2 | 2022 | 72 | 1.100 |
Why?
|
Granuloma | 3 | 2023 | 329 | 0.970 |
Why?
|
Nail Diseases | 2 | 2024 | 54 | 0.910 |
Why?
|
Epidermolysis Bullosa | 1 | 2024 | 29 | 0.900 |
Why?
|
Nevus, Blue | 1 | 2023 | 43 | 0.880 |
Why?
|
Neurocutaneous Syndromes | 2 | 2023 | 53 | 0.870 |
Why?
|
Sentinel Lymph Node Biopsy | 6 | 2023 | 734 | 0.850 |
Why?
|
Scalp Dermatoses | 1 | 2022 | 44 | 0.800 |
Why?
|
DNA, Neoplasm | 2 | 2020 | 1741 | 0.800 |
Why?
|
Callosities | 1 | 2021 | 5 | 0.790 |
Why?
|
Skin Diseases | 5 | 2024 | 1084 | 0.760 |
Why?
|
Sunburn | 2 | 2019 | 156 | 0.760 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 26 | 0.750 |
Why?
|
Child | 43 | 2024 | 80670 | 0.750 |
Why?
|
Nevus of Ota | 1 | 2021 | 3 | 0.750 |
Why?
|
Granuloma, Pyogenic | 1 | 2021 | 47 | 0.740 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2024 | 456 | 0.730 |
Why?
|
Skin Abnormalities | 1 | 2021 | 60 | 0.730 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2020 | 14 | 0.730 |
Why?
|
Penicillamine | 1 | 2020 | 60 | 0.730 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 73 | 0.710 |
Why?
|
Carcinoma, Basal Cell | 3 | 2020 | 565 | 0.700 |
Why?
|
Nevus | 1 | 2022 | 205 | 0.700 |
Why?
|
Cumulative Trauma Disorders | 1 | 2021 | 152 | 0.680 |
Why?
|
Fingers | 1 | 2021 | 508 | 0.620 |
Why?
|
Aluminum Compounds | 1 | 2018 | 56 | 0.600 |
Why?
|
Acne Vulgaris | 1 | 2022 | 352 | 0.570 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4349 | 0.550 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 491 | 0.540 |
Why?
|
Urticaria | 1 | 2018 | 151 | 0.530 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.510 |
Why?
|
Cleft Lip | 1 | 2021 | 512 | 0.510 |
Why?
|
Drug Eruptions | 3 | 2014 | 335 | 0.500 |
Why?
|
Cleft Palate | 1 | 2021 | 596 | 0.500 |
Why?
|
Sweat Gland Diseases | 1 | 2015 | 12 | 0.500 |
Why?
|
Chlorides | 1 | 2018 | 666 | 0.480 |
Why?
|
Eccrine Glands | 1 | 2015 | 52 | 0.480 |
Why?
|
Child, Preschool | 21 | 2024 | 42577 | 0.470 |
Why?
|
Urinary Bladder | 5 | 2008 | 1155 | 0.460 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2801 | 0.450 |
Why?
|
Infant | 18 | 2024 | 36459 | 0.450 |
Why?
|
Dermatitis, Atopic | 4 | 2024 | 734 | 0.450 |
Why?
|
Humans | 88 | 2024 | 766812 | 0.450 |
Why?
|
Adolescent | 27 | 2024 | 88902 | 0.450 |
Why?
|
Abnormalities, Multiple | 1 | 2021 | 1424 | 0.450 |
Why?
|
Leg Injuries | 1 | 2015 | 180 | 0.430 |
Why?
|
Biopsy | 7 | 2021 | 6779 | 0.420 |
Why?
|
Hamartoma | 1 | 2015 | 235 | 0.410 |
Why?
|
Diagnosis, Differential | 8 | 2024 | 12985 | 0.400 |
Why?
|
Giant Cells | 1 | 2013 | 187 | 0.400 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 926 | 0.400 |
Why?
|
Telemedicine | 4 | 2022 | 3111 | 0.390 |
Why?
|
Language | 1 | 2021 | 1550 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 2 | 2012 | 1805 | 0.380 |
Why?
|
Clobetasol | 2 | 2014 | 33 | 0.380 |
Why?
|
Cyclin D1 | 1 | 2013 | 453 | 0.360 |
Why?
|
Scalp | 2 | 2023 | 390 | 0.340 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 542 | 0.340 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 84 | 0.320 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1100 | 0.310 |
Why?
|
Pathology, Clinical | 1 | 2012 | 374 | 0.300 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 329 | 0.300 |
Why?
|
Exocytosis | 3 | 2008 | 323 | 0.290 |
Why?
|
Eczema | 2 | 2018 | 244 | 0.250 |
Why?
|
Mutation | 2 | 2024 | 30214 | 0.250 |
Why?
|
Vaccination | 1 | 2018 | 3435 | 0.250 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7475 | 0.240 |
Why?
|
Cafe-au-Lait Spots | 1 | 2024 | 20 | 0.230 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36570 | 0.230 |
Why?
|
Retrospective Studies | 17 | 2024 | 81657 | 0.230 |
Why?
|
Female | 37 | 2024 | 396532 | 0.230 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2056 | 0.220 |
Why?
|
Hospitalization | 1 | 2024 | 10816 | 0.220 |
Why?
|
Male | 33 | 2024 | 364154 | 0.220 |
Why?
|
Azetidines | 1 | 2024 | 151 | 0.210 |
Why?
|
Immunohistochemistry | 5 | 2024 | 11062 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1884 | 0.200 |
Why?
|
Trientine | 1 | 2020 | 12 | 0.190 |
Why?
|
Pamphlets | 1 | 2020 | 71 | 0.180 |
Why?
|
Young Adult | 11 | 2024 | 59939 | 0.170 |
Why?
|
Melanins | 1 | 2022 | 291 | 0.170 |
Why?
|
Glucocorticoids | 2 | 2021 | 2158 | 0.170 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4559 | 0.170 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2021 | 148 | 0.170 |
Why?
|
Genomics | 2 | 2022 | 5922 | 0.170 |
Why?
|
Aminoquinolines | 1 | 2020 | 105 | 0.170 |
Why?
|
Lip | 1 | 2021 | 196 | 0.170 |
Why?
|
Immunologic Factors | 2 | 2022 | 1594 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4050 | 0.150 |
Why?
|
Ambulatory Care Facilities | 2 | 2021 | 939 | 0.150 |
Why?
|
Communication Barriers | 1 | 2021 | 418 | 0.150 |
Why?
|
Hospital Costs | 1 | 2024 | 955 | 0.150 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2008 | 179 | 0.150 |
Why?
|
Patch Tests | 1 | 2018 | 57 | 0.140 |
Why?
|
Sunlight | 1 | 2019 | 336 | 0.140 |
Why?
|
Remote Consultation | 1 | 2020 | 241 | 0.140 |
Why?
|
Histamine Antagonists | 1 | 2018 | 93 | 0.140 |
Why?
|
Age of Onset | 1 | 2024 | 3343 | 0.140 |
Why?
|
Urination | 1 | 2008 | 204 | 0.140 |
Why?
|
Adult | 15 | 2024 | 223305 | 0.140 |
Why?
|
rab GTP-Binding Proteins | 1 | 2008 | 247 | 0.140 |
Why?
|
Comparative Genomic Hybridization | 1 | 2018 | 474 | 0.130 |
Why?
|
Antibodies, Monoclonal | 2 | 2012 | 9244 | 0.130 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6548 | 0.130 |
Why?
|
Down Syndrome | 1 | 2024 | 916 | 0.130 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5753 | 0.130 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 4 | 0.120 |
Why?
|
Dermatitis, Phototoxic | 1 | 2014 | 17 | 0.120 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5513 | 0.120 |
Why?
|
Neurons, Afferent | 1 | 2007 | 498 | 0.120 |
Why?
|
Parents | 2 | 2019 | 3592 | 0.120 |
Why?
|
Fluorouracil | 1 | 2020 | 1652 | 0.120 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1615 | 0.120 |
Why?
|
Mohs Surgery | 1 | 2017 | 217 | 0.110 |
Why?
|
Receptors, Purinergic P2 | 1 | 2005 | 151 | 0.110 |
Why?
|
Hyperalgesia | 1 | 2008 | 527 | 0.110 |
Why?
|
Photography | 1 | 2017 | 536 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2019 | 769 | 0.110 |
Why?
|
Urothelium | 1 | 2005 | 275 | 0.110 |
Why?
|
Prognosis | 4 | 2023 | 29959 | 0.110 |
Why?
|
Interferons | 1 | 2017 | 716 | 0.110 |
Why?
|
Physostigmine | 1 | 2002 | 50 | 0.100 |
Why?
|
Estrous Cycle | 1 | 2002 | 65 | 0.100 |
Why?
|
Leg | 1 | 2018 | 1087 | 0.100 |
Why?
|
Boston | 2 | 2023 | 9346 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2018 | 904 | 0.100 |
Why?
|
Administration, Topical | 2 | 2014 | 702 | 0.100 |
Why?
|
Laminin | 1 | 2014 | 404 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 200 | 0.100 |
Why?
|
Pemphigoid, Bullous | 1 | 2014 | 110 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2510 | 0.100 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 349 | 0.090 |
Why?
|
Infant, Newborn | 4 | 2024 | 26387 | 0.090 |
Why?
|
Lower Extremity | 2 | 2017 | 1217 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3610 | 0.090 |
Why?
|
Comorbidity | 2 | 2024 | 10580 | 0.090 |
Why?
|
Documentation | 1 | 2018 | 914 | 0.090 |
Why?
|
Cholinesterase Inhibitors | 1 | 2002 | 242 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3552 | 0.090 |
Why?
|
Rheumatoid Nodule | 1 | 2010 | 15 | 0.090 |
Why?
|
Survival Rate | 3 | 2024 | 12826 | 0.090 |
Why?
|
Measles | 1 | 2012 | 180 | 0.090 |
Why?
|
Necrobiosis Lipoidica | 1 | 2010 | 14 | 0.090 |
Why?
|
Xanthomatosis | 1 | 2010 | 32 | 0.090 |
Why?
|
Alopecia | 2 | 2018 | 416 | 0.090 |
Why?
|
Caregivers | 1 | 2022 | 2303 | 0.080 |
Why?
|
Risk Factors | 8 | 2023 | 74889 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2783 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 588 | 0.080 |
Why?
|
Cell Membrane | 2 | 2007 | 3642 | 0.080 |
Why?
|
Age Factors | 4 | 2020 | 18397 | 0.080 |
Why?
|
Cohort Studies | 5 | 2024 | 41706 | 0.080 |
Why?
|
Patient Compliance | 1 | 2019 | 2694 | 0.080 |
Why?
|
Pituitary-Adrenal System | 1 | 2002 | 553 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1794 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 668 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20710 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1062 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 2001 | 0.080 |
Why?
|
Patient Care Team | 2 | 2019 | 2519 | 0.080 |
Why?
|
Survivors | 1 | 2019 | 2379 | 0.080 |
Why?
|
Curriculum | 1 | 2022 | 3783 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2021 | 3618 | 0.080 |
Why?
|
Reference Standards | 1 | 2012 | 1010 | 0.080 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2002 | 702 | 0.080 |
Why?
|
Lichen Planus | 1 | 2009 | 70 | 0.080 |
Why?
|
Sjogren's Syndrome | 1 | 2010 | 240 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9407 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13489 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2013 | 1838 | 0.070 |
Why?
|
Dermatitis | 1 | 2010 | 203 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2649 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2010 | 15831 | 0.070 |
Why?
|
Physicians | 2 | 2023 | 4591 | 0.070 |
Why?
|
United States | 7 | 2024 | 72945 | 0.070 |
Why?
|
Interleukins | 1 | 2012 | 796 | 0.070 |
Why?
|
Massachusetts | 1 | 2020 | 8890 | 0.070 |
Why?
|
Eosinophils | 1 | 2012 | 952 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1097 | 0.070 |
Why?
|
Paraproteinemias | 1 | 2010 | 251 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8540 | 0.070 |
Why?
|
Lipomatosis | 1 | 2007 | 112 | 0.070 |
Why?
|
Biological Specimen Banks | 1 | 2012 | 787 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1405 | 0.070 |
Why?
|
Appointments and Schedules | 2 | 2020 | 442 | 0.070 |
Why?
|
Intestine, Small | 1 | 2012 | 1217 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4114 | 0.060 |
Why?
|
Hair | 1 | 2009 | 508 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4215 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2115 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11218 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3591 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1276 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 2012 | 2730 | 0.060 |
Why?
|
Sarcoidosis | 1 | 2010 | 535 | 0.060 |
Why?
|
Incidence | 2 | 2020 | 21527 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 26309 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 4056 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2019 | 10451 | 0.050 |
Why?
|
Immunotherapy | 1 | 2019 | 4747 | 0.050 |
Why?
|
Methotrexate | 1 | 2010 | 1719 | 0.050 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3235 | 0.050 |
Why?
|
Skin Pigmentation | 1 | 2024 | 278 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2010 | 1429 | 0.050 |
Why?
|
Risk Assessment | 3 | 2023 | 24299 | 0.050 |
Why?
|
Hypertrichosis | 1 | 2021 | 31 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 296 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39312 | 0.050 |
Why?
|
Skin Care | 1 | 2021 | 54 | 0.050 |
Why?
|
Hair Removal | 1 | 2021 | 41 | 0.050 |
Why?
|
Middle Aged | 8 | 2024 | 223267 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13644 | 0.050 |
Why?
|
Purines | 1 | 2024 | 615 | 0.050 |
Why?
|
Electronics | 1 | 2021 | 315 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1383 | 0.040 |
Why?
|
Rabbits | 2 | 2007 | 4752 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3079 | 0.040 |
Why?
|
Stem Cells | 1 | 2012 | 3536 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1900 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2126 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2024 | 935 | 0.040 |
Why?
|
Cytoplasmic Vesicles | 1 | 2008 | 72 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2024 | 65286 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2022 | 2012 | 0.040 |
Why?
|
Pruritus | 1 | 2021 | 378 | 0.040 |
Why?
|
Reflex, Abnormal | 1 | 2008 | 83 | 0.040 |
Why?
|
Primary Health Care | 3 | 2020 | 4735 | 0.040 |
Why?
|
Emollients | 1 | 2018 | 41 | 0.040 |
Why?
|
Cystitis | 1 | 2008 | 96 | 0.040 |
Why?
|
Baths | 1 | 2018 | 52 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5330 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2010 | 2160 | 0.040 |
Why?
|
Cell Shape | 1 | 2008 | 372 | 0.040 |
Why?
|
Crohn Disease | 1 | 2010 | 2286 | 0.030 |
Why?
|
Vitiligo | 1 | 2018 | 97 | 0.030 |
Why?
|
Neutrophils | 1 | 2010 | 3782 | 0.030 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 551 | 0.030 |
Why?
|
Transforming Growth Factor alpha | 1 | 2007 | 134 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8623 | 0.030 |
Why?
|
Cycloheximide | 1 | 2007 | 340 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2008 | 487 | 0.030 |
Why?
|
Quality of Life | 1 | 2018 | 13476 | 0.030 |
Why?
|
Nurse Practitioners | 1 | 2019 | 270 | 0.030 |
Why?
|
Disease Management | 2 | 2018 | 2533 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16722 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4019 | 0.030 |
Why?
|
Patients | 1 | 2023 | 908 | 0.030 |
Why?
|
Capital Financing | 1 | 2016 | 58 | 0.030 |
Why?
|
Electric Capacitance | 1 | 2005 | 11 | 0.030 |
Why?
|
Office Visits | 1 | 2020 | 593 | 0.030 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2005 | 8 | 0.030 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2005 | 9 | 0.030 |
Why?
|
Purinergic P2 Receptor Agonists | 1 | 2005 | 13 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2012 | 14473 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2008 | 899 | 0.030 |
Why?
|
Physical Examination | 1 | 2021 | 1265 | 0.030 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 123 | 0.030 |
Why?
|
Waiting Lists | 1 | 2020 | 779 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27158 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 2598 | 0.030 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 22 | 0.030 |
Why?
|
Sulfonamides | 1 | 2024 | 1982 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1949 | 0.030 |
Why?
|
Research | 1 | 2023 | 1977 | 0.030 |
Why?
|
Clindamycin | 1 | 2014 | 138 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 697 | 0.030 |
Why?
|
Population Surveillance | 1 | 2024 | 2594 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20146 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2030 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8108 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1140 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2008 | 640 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 915 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 59548 | 0.030 |
Why?
|
Time Factors | 2 | 2018 | 40149 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2007 | 659 | 0.030 |
Why?
|
Mice | 5 | 2022 | 81898 | 0.030 |
Why?
|
Minocycline | 1 | 2014 | 170 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1596 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 482 | 0.030 |
Why?
|
Apyrase | 1 | 2005 | 376 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 2002 | 125 | 0.030 |
Why?
|
Epithelium | 1 | 2007 | 1606 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2426 | 0.030 |
Why?
|
Sensory Receptor Cells | 1 | 2007 | 509 | 0.030 |
Why?
|
Sampling Studies | 1 | 2014 | 614 | 0.030 |
Why?
|
Tyrosine | 1 | 2007 | 1425 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 305 | 0.030 |
Why?
|
Motivation | 1 | 2022 | 2020 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 22351 | 0.020 |
Why?
|
Radiotherapy | 1 | 2019 | 1497 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3043 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1244 | 0.020 |
Why?
|
Corticosterone | 1 | 2002 | 301 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1404 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 712 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2013 | 303 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2013 | 861 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 389 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2014 | 385 | 0.020 |
Why?
|
Receptors, Interleukin | 1 | 2012 | 243 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5888 | 0.020 |
Why?
|
Aged | 4 | 2024 | 171344 | 0.020 |
Why?
|
Endocytosis | 1 | 2005 | 951 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2013 | 257 | 0.020 |
Why?
|
Interleukin-23 | 1 | 2012 | 202 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2002 | 618 | 0.020 |
Why?
|
Wound Healing | 1 | 2021 | 2800 | 0.020 |
Why?
|
Animals | 6 | 2022 | 168939 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 925 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2680 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2002 | 505 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1657 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 890 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4523 | 0.020 |
Why?
|
Melanocytes | 1 | 2013 | 509 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2014 | 865 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2334 | 0.020 |
Why?
|
Glycoproteins | 1 | 2007 | 2201 | 0.020 |
Why?
|
Signal Transduction | 3 | 2007 | 23618 | 0.020 |
Why?
|
Rats | 2 | 2007 | 23717 | 0.020 |
Why?
|
Pyridones | 1 | 2014 | 818 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1252 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1088 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1168 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 18076 | 0.020 |
Why?
|
Pain Measurement | 1 | 2008 | 3576 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 2085 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21162 | 0.020 |
Why?
|
Health Care Reform | 1 | 2016 | 1256 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3230 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 8310 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1285 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2007 | 3698 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2012 | 6225 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5536 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2841 | 0.010 |
Why?
|
Pediatrics | 1 | 2018 | 3614 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3850 | 0.010 |
Why?
|
Health Personnel | 1 | 2016 | 3384 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2823 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5783 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5890 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22248 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 22350 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8734 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15912 | 0.010 |
Why?
|
Sex Factors | 1 | 2002 | 10619 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5367 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9514 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13642 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 17089 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18329 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 17532 | 0.000 |
Why?
|